Additional file 1: of Lipid profile status and other related factors in patients with Hyperphenylalaninaemia

Characteristics of Hyperphenylalaninaemia patients with altered values of the biochemical parameters studied. (DOCX 85 kb

Additional file 1: of Carbohydrate status in patients with phenylketonuria

Clinical and basal biochemical characteristics of each patient with hyperphenylalaninemia. (DOCX 48 kb

Additional file 2: of Carbohydrate status in patients with phenylketonuria

Clinical and biochemical characteristics of healthy controls. (DOCX 21 kb

Measures of pmTOR/mTOR levels in gastric mucosa and representative Western blots from animals in the fasting state treated with ip rimonabant and/or ip rapamycin chronically for 1 week (A).

<p>Phospho-S6K1/S6K1 in gastric mucosae from animals in the fasting state treated with rimonabant ip and/or rapamycin ip chronically for 1 week (B). The results are expressed as percentages over control (phospho-S6K1/S6K1). *p<0.05, vs control; ^#p<0.05 vs rimonabant. C: control, R: rimonabant, Ra: rapamycin; Ra+R: rapamycin+rimonabant.</p

Primers for the real time qPCR analyses.

<p>Primers for the real time qPCR analyses.</p

Food Intake measures in rats after icv treatment with ghrelin/vehicle (6 µg/rat) and ip treatment with rimonabant (3 mg/kg ip)/vehicle under different nutritional statuses: A) <i>Ad libitum</i> fed, B) nocturnal fasting, c) animals subjected to overnight fasting and previously subjected to surgical vagotomy.

<p>*vs control, ^#vs. rimonabant+ghrelin.</p

Measures of pmTOR/mTOR in the gastric mucosae and representative Western blots from animals in the fasting state treated with ip AM281 or vehicle (A).

<p>Phospho-S6K1/S6K1 in the gastric mucosae and representative Western blots from animals in the fasting state treated with ip AM281 or vehicle (control) (B). The results are expressed as percentage over control (phospho-S6K1/S6K1). *p<0.05.</p

mRNA expression levels measured by real-time PCR for ghrelin in <i>ad libitum</i> fed animals (A) or 36-hour fasted animals (B).

<p>Ghrelin protein levels and representative Western blot from the mucosa from <i>ad libitum</i> fed animals (C) or 36-hours fasted animals (D). Animals that received different in vivo treatments (control/rimonabant) and surgical procedures (vagotomy/sham-operated). C: control, R: rimonabant, V: vagotomy; V+R: vagotomy+rimonabant. CB1 receptor mRNA levels in the gastric mucosae of <i>ad libitum</i> fed animals (E) or 36-hour fasted animals (F) and animals that received different in vivo treatments (control/rimonabant) and surgical procedures (vagotomy/sham operated). *vs control.</p

Gastric ghrelin secretion from tissue explants (A) and plasma ghrelin levels (B) obtained from 36-hour fasted animals that received in vivo treatment with AM281 (3 mg/Kg ip).

<p>**p<0.01.</p

Gastric ghrelin secretion from tissue explants obtained from <i>ad libitum</i> fed animals (A) or 36-hour fasted animals (B) and plasma ghrelin levels from <i>ad libitum</i> fed animals (C) or 36-hour fasted animals (D) under different in vivo treatments (control/rimonabant), and surgical procedures (vagotomy/sham operated).

<p>Gastric ghrelin secretion from tissue explants from <i>ad libitum</i> fed animals (E) or 36-hour fasted animals (F) under different in vitro treatments (control/rimonabant) and surgical procedures (vagotomy/sham operated). *vs control.</p